Celyad Oncology SA (CYAD.BR)

EUR 0.71

(-7.42%)

Revenue Summary of Celyad Oncology SA

  • Celyad Oncology SA's latest annual revenue in 2023 was 102 Thousand EUR , down 0.0% from previous year.
  • Celyad Oncology SA's latest quarterly revenue in 2024 Q2 was 14 Thousand EUR , down 0.0% from previous quarter.
  • Celyad Oncology SA reported a annual revenue of - EUR in annual revenue 2022, down 0.0% from previous year.
  • Celyad Oncology SA reported a annual revenue of - EUR in annual revenue 2021, down -100.0% from previous year.
  • Celyad Oncology SA reported a quarterly revenue of 102 Thousand EUR for 2023 FY, down 0.0% from previous quarter.
  • Celyad Oncology SA reported a quarterly revenue of 58 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Revenue Chart of Celyad Oncology SA (2023 - 2011)

Historical Annual Revenue of Celyad Oncology SA (2023 - 2011)

Year Revenue Revenue Growth
2023 102 Thousand EUR 0.0%
2022 - EUR 0.0%
2021 - EUR -100.0%
2020 5000.00 EUR -16.67%
2019 6000.00 EUR -99.81%
2018 3.11 Million EUR -12.01%
2017 3.54 Million EUR -58.47%
2016 8.52 Million EUR 284000.0%
2015 3000.00 EUR -97.95%
2014 146 Thousand EUR 0.0%
2013 - EUR -100.0%
2012 54 Thousand EUR 100.5%
2011 26.93 Thousand EUR 0.0%

Peer Revenue Comparison of Celyad Oncology SA

Name Revenue Revenue Difference
ABIONYX Pharma SA 4.64 Million EUR 97.802%
ABIVAX Société Anonyme 4.62 Million EUR 97.793%
Adocia SA 2.15 Million EUR 95.256%
Aelis Farma SA 9.05 Million EUR 98.873%
Biophytis S.A. - EUR -Infinity%
Advicenne S.A. 3.15 Million EUR 96.763%
genOway Société anonyme 20.04 Million EUR 99.491%
IntegraGen SA 12.53 Million EUR 99.186%
Medesis Pharma S.A. 300.03 Thousand EUR 66.004%
Neovacs S.A. 533.41 Thousand EUR 80.878%
NFL Biosciences SA - EUR -Infinity%
Plant Advanced Technologies SA 1.68 Million EUR 93.934%
Quantum Genomics Société Anonyme 19.79 Thousand EUR -415.256%
Sensorion SA 4.74 Million EUR 97.849%
Theranexus Société Anonyme 296.33 Thousand EUR 65.579%
TME Pharma N.V. 17 Thousand EUR -500.0%
Valbiotis SA 4.73 Million EUR 97.845%
TheraVet SA 1.07 Million EUR 90.539%
Valerio Therapeutics Société anonyme 1.8 Million EUR 94.333%
argenx SE 1.13 Billion EUR 99.991%
BioSenic S.A. 543 Thousand EUR 81.215%
DBV Technologies S.A. - EUR -Infinity%
Galapagos NV 239.72 Million EUR 99.957%
Genfit S.A. 28.56 Million EUR 99.643%
GeNeuro SA - EUR -Infinity%
Hyloris Pharmaceuticals SA 2.08 Million EUR 95.113%
Innate Pharma S.A. 51.9 Million EUR 99.803%
Inventiva S.A. 17.47 Million EUR 99.416%
MaaT Pharma SA 2.22 Million EUR 95.422%
MedinCell S.A. 9.16 Million EUR 98.886%
Nanobiotix S.A. 30.05 Million EUR 99.661%
Onward Medical N.V. 532 Thousand EUR 80.827%
Oryzon Genomics S.A. 14.19 Million EUR 99.281%
OSE Immunotherapeutics SA 2.22 Million EUR 95.42%
Oxurion NV 263 Thousand EUR 61.217%
Pharming Group N.V. 245.31 Million EUR 99.958%
Poxel S.A. 1.98 Million EUR 94.851%
GenSight Biologics S.A. 1.26 Million EUR 91.949%
Transgene SA 1.18 Million EUR 91.385%
Financière de Tubize SA - EUR -Infinity%
UCB SA 5.25 Billion EUR 99.998%
Valneva SE 153.71 Million EUR 99.934%
Vivoryon Therapeutics N.V. -3.62 Million EUR 102.818%